Concord Drugs Complete Financial Statements
In FY2026, Concord Drugs (CONCORD) reported revenue ₹38 Cr, net profit ₹1 Cr and EPS ₹0.47, with a net profit margin of 2.6% and ROE of 2.0%. Full financial statements from FY2022 to FY2026 (5 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Examine CONCORD quarterly trends for recent quarterly revenue, profit and EPS trends.
Complete Financial Data Export
Profitability Ratios
Balance Sheet Ratios
CONCORD Revenue, Net Profit & EBITDA — Year-on-Year Growth
CONCORD YoY (Mar 2025 vs Mar 2026) — revenue +280.0%, EBITDA +100.0%, expenses +300.0%. For live price, earnings ratios and company overview, see CONCORD share price screener.
CONCORD Income Statement — Revenue, EBITDA & Net Profit
Concord Drugs revenue ₹38 Cr, EBITDA ₹2 Cr, net profit ₹1 Cr, EPS ₹0.47 (2026) — net profit margin 2.6%. Analyse CONCORD shareholding pattern to track promoter, FII and institutional holdings.
| Particulars | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | Mar 2024 | Jun 2024 | Dec 2024 | Sept 2023 | Mar 2023 | Jun 2023 | Dec 2023 | Sept 2022 | Mar 2022 | Jun 2022 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 38 | 10 | 10 | 14 | 17 | 12 | 16 | 12 | 11 | 8 | 12 | 9 | 13 | 14 | 16 | 13 | 14 |
| Expenses | 36 | 9 | 9 | 13 | 16 | 12 | 15 | 11 | 9 | 6 | 11 | 8 | 12 | 13 | 15 | 12 | 12 |
| EBITDA | 2 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 2 | 1 | 2 | 1 | 1 | 1 | 1 | 1 |
| Operating Profit Margin % | 4.00% | 11.00% | 10.00% | 7.00% | 5.00% | 7.00% | 2.00% | 7.00% | 13.00% | 21.00% | 8.00% | 16.00% | 5.00% | 9.00% | 4.00% | 8.00% | 11.00% |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Interest | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 1 | 0 | 0 | 0 | 0 | 0 | -1 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Earnings Per Share (₹) | 0.47 | 0.19 | 0.04 | 0.12 | 0.16 | 0.04 | -0.34 | 0.03 | 0.23 | 0.60 | 0.17 | 0.53 | -0.24 | 0.21 | 0.03 | 0.21 | 0.52 |
CONCORD Balance Sheet — Assets, Liabilities & Shareholders' Equity
CONCORD total assets ₹75 Cr, total equity ₹49 Cr, total liabilities ₹ Cr (2026) — ROE 2.0%.
| Particulars | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| ASSETS | |||||
| Total Assets | 75 | 65 | 59 | 58 | 56 |
| Current Assets | 53 | 41 | 38 | 44 | 42 |
| Fixed Assets | 14 | 12 | 12 | 13 | 14 |
| Capital Work in Progress | 2 | 2 | 2 | 1 | 1 |
| Investments | 26 | 1 | 1 | 1 | 0 |
| Other Assets | 0 | 50 | 45 | 44 | 42 |
| LIABILITIES | |||||
| Total Liabilities | |||||
| Current Liabilities | 5 | 5 | 4 | 5 | 4 |
| Non-Current Liabilities | |||||
| SHAREHOLDERS' EQUITY | |||||
| Total Equity | 49 | 34 | 34 | 32 | 28 |
| Share Capital | 13 | 10 | 10 | 9 | 9 |
| Reserves & Surplus | 35 | 24 | 24 | 22 | 20 |
CONCORD Cash Flow Statement — Operating, Investing & Financing
Concord Drugs operating cash flow ₹4 Cr, investing ₹-2 Cr, financing ₹-1 Cr, net cash flow ₹0 Cr (2025).
| Particulars | March 2025 | March 2024 | March 2023 | March 2022 |
|---|---|---|---|---|
| Operating Activities | 4 | 1 | 2 | 1 |
| Investing Activities | -2 | -1 | -2 | -2 |
| Financing Activities | -1 | 0 | 1 | 2 |
| Net Cash Flow | 0 | 0 | 0 | 0 |